Acute Cerebrovascular Disease and the Management of Raised Intracranial Pressure

  • Paul Ellis Marik


Stroke is the third most common cause of death in the United States, after heart disease and cancer. Over 500,000 Americans suffer a stroke each year, with approximately 175,000 of these patients dying from the acute event. In over 75% of cases, the stroke is ischemic in nature. However, unlike acute myocardial infarction, therapeutic interventions that attempt to limit infarct size have been of limited success. Indeed, apart from thrombolytic therapy in highly select groups of patients (probably <5% of “stroke” patients) and aspirin, no therapeutic intervention has been demonstrated to have an impact on the course of this illness. Considering these data, the rationale for admitting patients to an ICU needs to be evaluated. In addition, aspects of medical care that maximize the potential for recovery and limit complications need to be explored. In most instances, such treatment is best provided by specialized low-technology stroke units.


Cerebral Blood Flow Cerebral Perfusion Pressure Mean Arterial Blood Pressure Stroke Unit Embolic Stroke 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Selected References

  1. 1.
    Berge E, Abelnoor M, Nakstad PH, Sandset PM. Low molecular- weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. Lancet. 2000; 355:1205–1210.PubMedCrossRefGoogle Scholar
  2. 2.
    Berrouschot J, Sterker M, Bettin S, Köster J, Schneider D. Mortality of space-occupying (“malignant”) middle cerebral artery infarction under conservative intensive care. Intensive Care Med. 1998;24:620–623.PubMedCrossRefGoogle Scholar
  3. 3.
    Burtin P, Bollaert PE, Feldmann L, et al. Prognosis of stroke patients undergoing mechanical ventilation. Intensive Care Med. 1994;20:32–36.PubMedCrossRefGoogle Scholar
  4. 4.
    Collaborative systematic review of the randomized trials of organized inpatient (stroke unit) care after stroke. BMI 1997;314:1511–1159.Google Scholar
  5. 5.
    Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiac care. Part IV, special resuscitation situations: stroke. JAMA. 1992; 268:2242–2244.CrossRefGoogle Scholar
  6. 6.
    Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Circulation. 1994; 90:1588–1601.Google Scholar
  7. 7.
    Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-AustralasianAcute Stroke Study Investigators.Lancet. 1998;352:1245–1251.PubMedCrossRefGoogle Scholar
  8. 8.
    Intravenous tissue-type plasminogen activator for treatment of acute stroke. The Standard Treatment with Alteplase to Reverse Stroke (STARS) Study. JAMA. 2000;283:1145–1150.CrossRefGoogle Scholar
  9. 9.
    Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke. The Cleveland area experience. JAMA. 2000;283:1151–1158.PubMedCrossRefGoogle Scholar
  10. 10.
    Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischemic stroke. A randomized controlled trial.JAMA. 1998; 279:1265–1272.Google Scholar
  11. 11.
    Muizelaar JP, Marmarou A, Ward JD, et al. Adverse effects of prolonged hyperventilation in patients with severe head injury: a randomized clinical trial.J Neurosurg 1991;75:731–739.PubMedCrossRefGoogle Scholar
  12. 12.
    NINDS rt PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–1587.CrossRefGoogle Scholar
  13. 13.
    O’Connell JE, Gray CS. Treatment of post-stroke hypertension. A practical guide. Drugs & Aging. 1996;8:408–415.CrossRefGoogle Scholar
  14. 14.
    Poungvarin N, Bhoopat W, Viriyavejakul, et al. Effects of dexamethasone in primary supratentorial intracerebral hemorrhage. N Engl J Med. 1987; 316:1229–1233.PubMedCrossRefGoogle Scholar
  15. 15.
    Qureshi AI, Bliwise DL, Bliwise NG, et al. Rate of 24-hour blood pressure decline and mortality after spontaneous intracerebral hemorrhage: a retrospective analysis with a random effects regression model. Crit Care Med. 1999;27:480–485.PubMedCrossRefGoogle Scholar
  16. 16.
    The International Stroke Trial (1ST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet. 1997;349:1569–1581.Google Scholar
  17. 17.
    Wallace JD, Levy LL. Blood pressure after stroke. JAMA. 1981;246: 2177–2180.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 2001

Authors and Affiliations

  • Paul Ellis Marik
    • 1
  1. 1.Critical Care MedicineMercy Hospital of PittsburghPittsburghUSA

Personalised recommendations